This is a preview of subscription content, log in via an institution to check access.
Notes
Both studies were sponsored by Novartis Pharmaceuticals.
References
Cariou C, et al. Cost-Effectiveness Analysis of Voretigene Neparvovec Versus Best Supportive Care in Patients with Rpe65-Mediated Inherited Retinal Dystrophy- a French Healthcare System Perspective. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. CC3, 2 Nov 2019. Available from: URL: https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2019/program/program
Ploug U. Cost-Effectiveness of Voretigene Neparvovec for Vision Loss Due to Biallelic Rpe65-Mediated Inherited Retinal Disease in a Danish Setting. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus oral presentation) abstr. PRO29, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/98088
Rights and permissions
About this article
Cite this article
Voretigene neparvovec good value in inherited retinal disease. PharmacoEcon Outcomes News 842, 32 (2019). https://doi.org/10.1007/s40274-019-6424-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6424-2